Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
06:00am, Thursday, 05'th Mar 2026
Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers mo
Zepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share pricing available to employ
Forget AI. This Biotech Stock's Taking Off Right Now
03:30pm, Wednesday, 04'th Mar 2026
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question mar
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
10:50am, Wednesday, 04'th Mar 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Top Growth Stocks to Buy in the First Half of 2026
07:15pm, Tuesday, 03'rd Mar 2026
Eli Lilly should continue to post top-line growth well above the industry average. Veeva Systems has lots of fuel to achieve its ambitious 2030 goal.
Baron Health Care Fund Q4 2025 Contributors And Detractors
10:18am, Tuesday, 03'rd Mar 2026
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 03'rd Mar 2026
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
05:57pm, Monday, 02'nd Mar 2026
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
03:58pm, Monday, 02'nd Mar 2026
Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, �
Novo Nordisk to Spend €432 Million Expanding Irish Wegovy Production
03:25pm, Monday, 02'nd Mar 2026
Novo Nordisk (NVO) is moving decisively to reinforce its manufacturing base, announcing a â¬432 million ($507 million) investment to upgrade and retrofit its A
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree
01:15pm, Monday, 02'nd Mar 2026
Eli Lilly's ongoing innovations could set the business up for a long time. The company also has a strong dividend program.
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
12:46pm, Monday, 02'nd Mar 2026
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
10:57am, Monday, 02'nd Mar 2026
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo ex
What Smart Money Loves About Lilly
10:40am, Monday, 02'nd Mar 2026
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
09:40am, Monday, 02'nd Mar 2026
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
